Cardiac amyloidosis is increasingly recognized as an underdiagnosed cause of heart failure. This review article provides an overview of the role of multimodality cardiovascular imaging in raising the suspicion of cardiac amyloidosis, confirming the diagnosis, providing risk assessment and detection of myocardial changes in response to therapy. The clinical use of multimodality imaging in diagnosing cardiac amyloidosis is illustrated through a case-based approach. Finally, the emerging role of cardiac positron emission tomography as well as artificial intelligence in cardiac amyloidosis is discussed.